Midazolam - Nasus Pharma
Alternative Names: NS-003Latest Information Update: 06 Mar 2024
At a glance
- Originator Nasus Pharma
- Class 3-ring heterocyclic compounds; Antiepileptic drugs; Benzodiazepines; Chlorinated hydrocarbons; Fluorobenzenes; Hypnosedatives; Imidazoles; Sleep disorder therapies; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Seizures
Most Recent Events
- 06 Mar 2024 NASUS Pharma has patent protection for NASAX technology (Nasus Pharma pipeline, March 2024).
- 09 Jan 2024 Preclinical trials in Seizures in Israel (Intranasal) prior to January 2024 (Nasus Pharma pipeline, January 2024)